I think our biggest issue on SP is the failure to attract investment from the big instos. We did the share consolidation to enable this, but it is yet to get any traction. I am not sure why. If the market Cap is so undervalued what aren't they taking a stake? I think the risk is comparatively pretty low, they have a P2 result showing clinical significance, they have a capable delivery partner and revenue model. I am surprised at the low level of interest.
I think our biggest issue on SP is the failure to attract...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.86 |
Change
0.560(2.90%) |
Mkt cap ! $2.538B | |||
| Open | High | Low | Value | Volume |
| $19.80 | $20.00 | $19.40 | $3.777M | 191.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1060 | $19.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.87 | 209 | 1 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |